[Skip to Content]
[Skip to Content Landing]

Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children

Educational Objective
To evaluate the association between proton pump inhibitor use and risk of fracture in children.
1 Credit CME
Key Points

Question  Is proton pump inhibitor (PPI) use associated with increased risk of fracture in children?

Findings  This pediatric cohort compared 115 933 patients who initiated PPI use with 115 933 matched individuals who did not initiate use and found that PPI use was associated with an 11% increased risk of fracture, a significant difference.

Meaning  These data suggest that PPI use is associated with a small increased risk of fracture in children; the findings inform safety considerations when these drugs are prescribed to pediatric patients.

Abstract

Importance  Proton pump inhibitor (PPI) use has been linked to increased risk of fracture in adults. Despite a trend in prescription of PPIs in children, there is scarce evidence regarding this safety concern in pediatric patients.

Objective  To evaluate the association between PPI use and risk of fracture in children.

Design  This nationwide register-based cohort study included data from Sweden from July 2006 to December 2016. Children younger than 18 years who initiated PPI use were matched on propensity score and age with those who did not initiate PPI use.

Exposure  Initiation of PPI use.

Main Outcomes and Measures  Cox regression was adopted to estimate hazard ratios (HRs) for a first fracture of any type and 5 subtypes of fracture, with follow-up for up to 5 years. To address potential residual confounding, high-dimensional propensity score matching and a direct comparison with histamine-2 receptor antagonists were performed.

Results  There were a total of 115 933 pairs of children included. During a mean (SD) of 2.2 (1.6) years of follow-up, 5354 and 4568 cases of any fracture occurred among those who initiated PPIs vs those who did not, respectively (20.2 vs 18.3 events per 1000 person-years; hazard ratio [HR], 1.11 [95% CI, 1.06-1.15]). Use of PPIs was associated with increased risk of upper-limb fracture (HR, 1.08 [95% CI, 1.03-1.13]), lower-limb fracture (HR, 1.19 [95% CI, 1.10-1.29]), and other fractures (HR, 1.51 [95% CI, 1.16-1.97]) but not head fracture (HR, 0.93 [95% CI, 0.76-1.13]) or spine fracture (HR, 1.31 [95% CI, 0.95-1.81]). The HRs for fracture according to cumulative duration of PPI use were 1.08 (95% CI, 1.03-1.13) for 30 days or less, 1.14 (95% CI, 1.09-1.20) for 31 to 364 days, and 1.34 (95% CI, 1.13-1.58) for 365 days or more. The association was consistent in most sensitivity analyses, including high-dimensional propensity score matching (HR, 1.10 [95% CI, 1.06-1.15]), although the analysis of PPI vs histamine-2 receptor antagonist did not reach statistical significance (HR, 1.06 [95% CI, 0.97-1.15]).

Conclusions and Relevance  In this large pediatric cohort, PPI use was associated with a small but significant increased risk of any fracture. Risk of fracture should be taken into account when weighing the benefits and risks of PPI treatment in children.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: December 4, 2019.

Corresponding Author: Yun-Han Wang, MSc, BPharm, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Eugeniahemmet T2, 171 76 Stockholm, Sweden (yun-han.wang@ki.se).

Published Online: March 16, 2020. doi:10.1001/jamapediatrics.2020.0007

Author Contributions: Ms Wang and Dr Pasternak had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Wang, Wintzell, Pasternak.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Wang.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Wang.

Obtained funding: Pasternak.

Administrative, technical, or material support: Wang, Wintzell, Pasternak.

Supervision: Pasternak.

Conflict of Interest Disclosures: Dr Svanström has received consulting fees from Celgene and is employed by IQVIA, outside of the submitted work. Dr Ludvigsson coordinates on behalf of the Swedish Inflammatory Bowel Disease Register (SWIBREG) a study that has received funding from Janssen Corporation. The other authors declare no conflicts of interest. No other disclosures were reported.

Funding/Support: Swedish Research Council and Frimurare Barnhuset Foundation supported this study, and Dr Pasternak was supported by an investigator grant from the Strategic Research Area Epidemiology program at Karolinska Institutet.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References
1.
Krishnan  U , Mousa  H , Dall’Oglio  L ,  et al.  ESPGHAN-NASPGHAN guidelines for the evaluation and treatment of gastrointestinal and nutritional complications in children with esophageal atresia-tracheoesophageal fistula.   J Pediatr Gastroenterol Nutr. 2016;63(5):550-570. doi:10.1097/MPG.0000000000001401 PubMedGoogle ScholarCrossref
2.
Rosen  R , Vandenplas  Y , Singendonk  M ,  et al.  Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.   J Pediatr Gastroenterol Nutr. 2018;66(3):516-554. doi:10.1097/MPG.0000000000001889 PubMedGoogle ScholarCrossref
3.
Hales  CM , Kit  BK , Gu  Q , Ogden  CL .  Trends in prescription medication use among children and adolescents-united states, 1999-2014.   JAMA. 2018;319(19):2009-2020. doi:10.1001/jama.2018.5690 PubMedGoogle ScholarCrossref
4.
De Bruyne  P , Ito  S .  Toxicity of long-term use of proton pump inhibitors in children.   Arch Dis Child. 2018;103(1):78-82. doi:10.1136/archdischild-2017-314026 PubMedGoogle ScholarCrossref
5.
Ward  RM , Kearns  GL .  Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.   Paediatr Drugs. 2013;15(2):119-131. doi:10.1007/s40272-013-0012-x PubMedGoogle ScholarCrossref
6.
Naranje  SM , Erali  RA , Warner  WC  Jr , Sawyer  JR , Kelly  DM .  Epidemiology of pediatric fractures presenting to emergency departments in the United States.   J Pediatr Orthop. 2016;36(4):e45-e48. doi:10.1097/BPO.0000000000000595 PubMedGoogle ScholarCrossref
7.
Yeh  FJ , Grant  AM , Williams  SM , Goulding  A .  Children who experience their first fracture at a young age have high rates of fracture.   Osteoporos Int. 2006;17(2):267-272. doi:10.1007/s00198-005-2009-y PubMedGoogle ScholarCrossref
8.
Thong  BKS , Ima-Nirwana  S , Chin  KY .  Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved.   Int J Environ Res Public Health. 2019;16(9):E1571. doi:10.3390/ijerph16091571 PubMedGoogle Scholar
9.
Liu  J , Li  X , Fan  L ,  et al.  Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis.   Life Sci. 2019;218:213-223. doi:10.1016/j.lfs.2018.12.058 PubMedGoogle ScholarCrossref
10.
Wagner  K , Wagner  S , Susi  A , Gorman  G , Hisle-Gorman  E .  Prematurity does not increase early childhood fracture risk.   J Pediatr. 2019;207:148-153. doi:10.1016/j.jpeds.2018.11.017 PubMedGoogle ScholarCrossref
11.
Malchodi  L , Wagner  K , Susi  A , Gorman  G , Hisle-Gorman  E .  Early acid suppression therapy exposure and fracture in young children.   Pediatrics. 2019;144(1):e20182625. doi:10.1542/peds.2018-2625 PubMedGoogle Scholar
12.
Freedberg  DE , Haynes  K , Denburg  MR ,  et al.  Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.   Osteoporos Int. 2015;26(10):2501-2507. doi:10.1007/s00198-015-3168-0 PubMedGoogle ScholarCrossref
13.
Ludvigsson  JF , Andersson  E , Ekbom  A ,  et al.  External review and validation of the Swedish national inpatient register.   BMC Public Health. 2011;11:450. doi:10.1186/1471-2458-11-450 PubMedGoogle ScholarCrossref
14.
Austin  PC .  Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations.   Biom J. 2009;51(1):171-184. doi:10.1002/bimj.200810488 PubMedGoogle ScholarCrossref
15.
Desai  RJ , Wyss  R , Jin  Y ,  et al.  Extension of disease risk score-based confounding adjustments for multiple outcomes of interest: an empirical evaluation.   Am J Epidemiol. 2018;187(11):2439-2448. doi:10.1093/aje/kwy130 PubMedGoogle Scholar
16.
Pan  BL , Huang  CF , Chuah  SK , Chiang  JC , Loke  SS .  Relationship between Helicobacter pylori infection and bone mineral density: a retrospective cross-sectional study.   BMC Gastroenterol. 2018;18(1):54. doi:10.1186/s12876-018-0780-4 PubMedGoogle ScholarCrossref
17.
Schneeweiss  S , Rassen  JA , Glynn  RJ , Avorn  J , Mogun  H , Brookhart  MA .  High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.   Epidemiology. 2009;20(4):512-522. doi:10.1097/EDE.0b013e3181a663cc PubMedGoogle ScholarCrossref
18.
Schneeweiss  S .  Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.   Pharmacoepidemiol Drug Saf. 2006;15(5):291-303. doi:10.1002/pds.1200 PubMedGoogle ScholarCrossref
19.
Ozen  G , Pedro  S , Wolfe  F , Michaud  K .  Medications associated with fracture risk in patients with rheumatoid arthritis.   Ann Rheum Dis. 2019;78(8):1041-1047. doi:10.1136/annrheumdis-2019-215328 PubMedGoogle ScholarCrossref
20.
Moayyedi  P , Eikelboom  JW , Bosch  J ,  et al; COMPASS Investigators.  Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin.   Gastroenterology. 2019;157(3):682-691.e2. doi:10.1053/j.gastro.2019.05.056PubMedGoogle ScholarCrossref
21.
Fedida  B , Schermann  H , Ankory  R ,  et al.  Fracture risk of young adults receiving proton-pump inhibitors and H2-receptor antagonists.   Int J Clin Pract. 2019;73(5):e13339. doi:10.1111/ijcp.13339 PubMedGoogle Scholar
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close